Back to top

Analyst Blog

Zacks Equity Research

Pernix Co-Promotes with Cumberland


 ZacksTrade Now

This page is temporarily not available.  Please check later as it should be available shortly. If you have any questions, please email customer support at or call 800-767-3771 ext.  9339.

Pernix Therapeutics, LLC has recently entered into a co-promotion agreement with Cumberland Pharmaceuticals Inc. for its gastroenterology drug, Omeclamox-Pak.

As per the terms of the agreement, Cumberland will promote the drug to gastroenterologists across the U.S. through its field sales force while Pernix will promote the product through its specialty sales force focusing on select primary care physicians.

We note that Omeclamox-Pak is indicated for the treatment of Helicobacter pylori (H. pylori) infection and duodenal ulcer disease. The drug was approved in the U.S. in 2011.

We remind investors that Pernix Therapeutics entered into a license and supply agreement with a privately-held company Gastro-Entero Logic for the rights of Omeclamox-Pak in 2012. 

Pernix promotes its branded products in two main segments – pediatric and gastroenterology products. Apart from Omeclamox-Pak, Pernix also has another drug, Rezyst, in its portfolio in the gastroenterology market. Rezyst is a probiotic blend to promote dietary management. 

In recent times, Pernix has been strengthening its product portfolio through acquisitions and promotion agreements.

Pernix completed the acquisitions of Cypress Pharma (a privately-owned generic pharmaceutical company) and Hawthorn Pharma (a privately-owned branded pharmaceutical company) at the end of Dec 2012. 

In early Mar 2013, Pernix completed the acquisition of Somaxon Pharmaceuticals, thereby adding insomnia drug Silenor to its portfolio.

Meanwhile, Pernix completed the sale of some of its non-core assets to privately-held Breckenridge Pharmaceutical in Sep 2013.

We are encouraged by Pernix’s efforts to consolidate its product portfolio.

Pernix currently carries a Zacks Rank #3 (Hold). Right now, Actavis, Inc. (ACT - Analyst Report) and Akorn, Inc. (AKRX - Snapshot Report) look attractive with a Zacks Rank #2 (Buy).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

Learn more

Start for as little as $4.50 per trade.

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
ANI PHARMACE ANIP 29.78 +16.56%
ALLIANCE FIB AFOP 17.95 +3.64%
FEDERATED NA FNHC 20.58 +3.57%
GREEN PLAINS GPRE 29.74 +2.73%
ULTRA CLEAN UCTT 11.29 +2.67%